Personalized Radiotherapy Shows Promise in Treating Muscle-Invasive Bladder Cancer
• A Phase 2 RAIDER trial investigated personalized, adaptive radiotherapy for muscle-invasive bladder cancer, tailoring treatment plans to individual bladder size and position.
• The study found that dose-escalated adaptive radiotherapy (DART) resulted in fewer serious long-term side effects compared to standard radiotherapy.
• Adaptive radiotherapy allowed for dose escalation to bladder tumors without significantly increasing toxicity, showing survival rates similar to cystectomy.
• Further research is planned to assess the effectiveness of adaptive radiotherapy in treating bladder cancer and improving patient outcomes.
© Copyright 2025. All Rights Reserved by MedPath